New trends in the study of podoplanin as a cell morphological regulator

Japanese Dental Science Review

Volumn 46, Issue 2, 2010, Pages 165-172

  Sawa, Yoshihiko ^a  

^a FUKUOKA DENTAL COLLEGE   (Japan)

Author keywords

Cancer; Podoplanin

Indexed keywords

EID: 77955051297     PISSN: 18827616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdsr.2010.01.003     Document Type: Review

References (74)

1. Breiteneder-Geleff S., Matsui K., Soleiman A., Meraner P., Poczewski H., Kalt R., et al. Podoplanin, novel43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol 1997, 151:1141-1152.
2. Dobbs L.G., Williams M.C., Gonzalez R. Monoclonal antibodies specific to apical surfaces of rat alveolar type I cells bind to surfaces of cultured, but not freshly isolated, type II cells. Biochim Biophys Acta 1988, 970:146-156.
3. Rishi A.K., Joyce-Brady M., Fisher J., Dobbs L.G., Floros J., VanderSpek J., et al. Cloning, characterization, and development expression of a rat lung alveolar type I cell gene in embryonic endodermal and neural derivatives. Dev Biol 1995, 167:294-306.
4. Ordóñez N.G. Podoplanin: a novel diagnostic immunohistochemical marker. Adv Anat Pathol 2006, 13:83-88.
5. Matsui K., Breiteneder-Geleff S., Kerjaschki D. Epitope specific antibodies to the 43kDa glomerular membrane protein podoplanin cause proteinuria and rapid flattening of podocytes. J Am Soc Nephrol 1998, 9:2013-2026.
6. Matsui K., Breitender-Geleff S., Soleiman A., Kowalski H., Kerjaschki D. Podoplanin, a novel 43-kDa membrane protein, controls the shape of podocytes. Nephrol Dial Transplant 1999, 14(Suppl. 1):9-11.
7. Koop K., Eikmans M., Wehland M., Baelde H., Ijpelaar D., Kreutz R., et al. Selective loss of podoplanin protein expression accompanies proteinuria and precedes alterations in podocyte morphology in a spontaneous proteinuric rat model. Am J Pathol 2008, 173:315-326.
8. Breiteneder-Geleff S., Soleiman A., Kowalski H., Horvat R., Amann G., Kriehuber E., et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999, 154:385-394.
9. Kriehuber E., Breiteneder-Geleff S., Groeger M., Soleiman A., Schoppmann S.F., Stingl G., et al. Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages. J Exp Med 2001, 194:797-808.
10. Schacht V., Ramirez M.I., Hong Y.K., Hirakawa S., Feng D., Harvey N., et al. T1α/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J 2003, 22:3546-3556.
11. Schacht V., Dadras S.S., Johnson L.A., Jackson D.G., Hong Y.K., Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 2005, 166:913-921.
12. Wigle J.T., Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell 1999, 98:769-778.
13. Hong Y.K., Harvey N., Noh Y.H., Schacht V., Hirakawa S., Detmar M. Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. Dev Dyn 2002, 225:351-357.
14. Petrova T.V., Makinen T., Makela T.P., Saarela J., Virtanen I., Ferrell R.E., et al. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J 2002, 21:4593-4599.
15. Hirakawa S., Hong Y.K., Harvey N., Schacht V., Matsuda K., Libermann T., et al. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol 2003, 162:575-586.
16. Gröger M., Loewe R., Holnthoner W., Embacher R., Pillinger M., Herron S.G., et al. Il-3 induces expression of lymphatic markers Prox-1 and podoplanin in human endothelial cells. J Immunol 2004, 173:7161-7169.
17. Ji R.C., Eshita Y., Kato S. Investigation of intratumoural and peritumoral lymphatics expressed by podoplanin and LYVE-1 in the hybridoma-induced tumours. Int J Exp Pathol 2007, 88:257-270.
18. Navarro A., Perez R.E., Rezaiekhaligh M., Mabry S.M., Ekekezie I.I. T1alpha/podoplanin is essential for capillary morphogenesis in lymphatic endothelial cells. Am J Physiol Lung Cell Mol Physiol 2008, 295:L543-551.
19. Sawa Y., Tsuruga E., Iwasawa K., Ishikawa H., Yoshida S. Leukocyte adhesion molecule and chemokine production through lipoteichoic acid recognition by toll-like receptor 2 in cultured human lymphatic endothelium. Cell Tissue Res 2008, 333:237-252.
20. Sawa Y., Tsuruga E. The expression of E-selectin and chemokines in the cultured human lymphatic endothelium with lipopolysaccharides. J Anat 2008, 212:654-663.
21. Sawa Y., Ueki T., Hata M., Iwasawa K., Tsuruga E., Kojima H., et al. LPS-induced IL-6, IL-8, VCAM-1, and ICAM-1 expression in human lymphatic endothelium. J Histochem Cytochem 2008, 56:97-109.
22. Hata M., Ueki T., Sato A., Kojima H., Sawa Y. Expression of podoplanin in the mouse salivary glands. Arch Oral Biol 2008, 53:835-841.
23. Nagato T., Yoshida H., Yoshida A., Uehara Y. A scanning electron microscope study of myoepithelial cells in exocrine glands. Cell Tissue Res 1980, 209:1-10.
24. Sawa Y., Iwasawa K., Ishikawa H. Expression of podoplanin in the mouse tooth germ and apical bud cells. Acta Histochem Cytochem 2008, 41:121-126.
25. Scholl F.G., Gamallo C., Vilar S., Quintanilla M. Identification of PA2.26 antigen as a novel cell-surface mucin-type glycoprotein that induces plasma membrane extensions and increased motility in keratinocytes. J. Cell Sci 1999, 112:4601-4613.
26. Yu Y., Khan J., Khanna C., Helman L., Meltzer P.S., Merlino G. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 2004, 10:175-181.
27. Martín-Villar E., Megías D., Castel S., Yurrita M.M., Vilaró S., Quintanilla M. Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci 2006, 119:4541-4553.
28. Wetterwald A., Hoffstetter W., Cecchini M.G., Lanske B., Wagner C., Fleisch H., et al. Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes. Bone 1996, 18:125-132.
29. Ordóñez N.G. D2-40 and podoplanin are highly specific and sensitive immuno-histochemical markers of epithelioid malignant mesothelioma. Hum Pathol 2005, 36:372-380.
30. Williams M.C., Cao Y., Hinds A., Rishi A.K., Wetterwald A. T1alpha protein is developmentally regulated and expressed by alveolar type I cells, choroid plexus and ciliary epithelia of adult rats. Am J Respir Cell Mol Biol 1996, 14:577-585.
31. Ramirez M.I., Millien G., Hinds A., Cao Y.X., Seldin D.C., Williams M.C. T1alpha, a lung type I cell differentiation gene, is required for normal lung cell proliferation and alveolous formation at birth. Dev Biol 2003, 256:61-72.
32. Yu H., Gibson J.A., Pinkus G.S., Hornick J.L. Podoplanin (D2-40) is a novel marker for follicular dendritic cell tumors. Am J Clin Pathol 2007, 128:776-782.
33. Raica M., Cimpean A.M., Ribatti D. The role of podoplanin in tumor progression and metastasis. Anticancer Res 2008, 28:2997-3006. Review.
34. Marsee D.K., Pinkus G.S., Hornick J.L. Podoplanin (D2-40) is a highly effective marker of follicular dendritic cells. Appl Immunohistochem Mol Morphol 2009, 17:102-107.
35. Zayed A.E., Abd-Elnaeim M.M., Abd-Elghaffar S.K., Hild A., Brehm R., Steger K. Prenatal development of murine gonads with special reference to germ cell differentiation: a morphological and immunohistochemical study. Andrologia 2007, 39:93-100.
36. Wicki A., Christofori G. The potential role of podoplanin in tumour invasion. Br J Cancer 2007, 96:1-5. Review.
37. Kato Y., Sasagawa I., Kaneko M., Osawa M., Fujita N., Tsuruo T. Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene 2004, 23:8552-8556.
38. Sonne S.B., Herlihy A.S., Hoei-Hansen C.E., Nielsen J.E., Almstrup K., Skakkebaek N.E., et al. Identity of M2A (D2-40) antigen and gp36 (Aggrus, T1α-2, podoplanin) in human developing testis, testicular carcinoma in situ and germ-cell tumours. Virchows Arch 2006, 449:200-206.
39. Yu H., Pinkus G.S., Hornick J.L. Diffuse membranous immunoreactivity for podoplanin (D2-40) distinguishes primary and metastatic seminomas from other germ cell tumors and metastatic neoplasms. Am J Clin Pathol 2007, 128:767-775.
40. Mishima K., Kato Y., Kaneko M.K., Nishikawa R., Hirose T., Matsutani M. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol 2006, 111:483-488.
41. Mishima K., Kato Y., Kaneko M.K., Nakazawa Y., Kunita A., Fujita N., et al. Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma. Acta Neuropathol 2006, 111:563-568.
42. Shibahara J., Kashima T., Kikuchi Y., Kunita A., Fukayama M. Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Arch 2006, 448:493-499.
43. Durchdewald M., Guinea-Viniegra J., Haag D., Riehl A., Lichter P., Hahn M., et al. Podoplanin is a novel fos target gene in skin carcinogenesis. Cancer Res 2008, 68:6877-6883.
44. Chu A.Y., Litzky L.A., Pasha T.L., Acs G., Zhang P.J. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 2005, 18:105-110.
45. Kimura N., Kimura I. Podoplanin as a marker for mesothelioma. Pathol Int 2005, 55:83-86.
46. Ordóñez N.G. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 2005, 36:372-380.
47. Padgett D.M., Cathro H.P., Wick M.R., Mills S.E. Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin. Am J Surg Pathol 2008, 32:123-127.
48. Martín-Villar E., Scholl F.G., Gamallo C., Yurrita M.M., Muñoz-Guerra M., Cruces J., et al. Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer 2005, 113:899-910.
49. Yuan P., Temam S., El-Naggar A., Zhou X., Liu D.D., Lee J.J., et al. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 2006, 107:563-569.
50. Kawaguchi H., El-Naggar A.K., Papadimitrakopoulou V., Ren H., Fan Y.H., Feng L., et al. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 2008, 26:354-360.
51. Kawase A., Ishii G., Nagai K., Ito T., Nagano T., Murata Y., et al. Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer 2008, 123:1053-1059.
52. Yamanashi T., Nakanishi Y., Fujii G., Akishima-Fukasawa Y., Moriya Y., Kanai Y., et al. Podoplanin expression identified in stromal fibroblasts as a favorable prognostic marker in patients with colorectal carcinoma. Oncology 2009, 77:53-62.
53. Kato Y., Kaneko M., Sata M., Fujita N., Tsuruo T., Osawa M. Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumour Biol 2005, 26:195-200.
54. Shimada Y., Ishii G., Nagai K., Atsumi N., Fujii S., Yamada A., et al. Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung. Cancer Sci 2009, 100:2054-2059.
55. Wicki A., Lehembre F., Wick N., Hantusch B., Kerjaschki D., Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 2006, 9:261-272.
56. Suzuki H., Kato Y., Kaneko M.K., Okita Y., Narimatsu H., Kato M. Induction of podoplanin by transforming growth factor-beta in human fibrosarcoma. FEBS Lett 2008, 582:341-345.
57. Hantusch B., Kalt R., Krieger S., Puri C., Kerjaschki D. Sp1/Sp3 and DNA-methylation contribute to basal transcriptional activation of human podoplanin in MG63 versus Saos-2 osteoblastic cells. BMC Mol Biol 2007, 8:20.
58. Suzuki-Inoue K., Kato Y., Inoue O., Kaneko M.K., Mishima K., Yatomi Y., et al. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem 2007, 282:25993-26001.
59. Kato Y., Kaneko M.K., Kunita A., Ito H., Kameyama A., Ogasawara S., et al. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Sci 2008, 99:54-61.
60. Kaneko M.K., Kato Y., Kitano T., Osawa M. Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. Gene 2006, 378:52-57.
61. Kato Y., Fujita N., Kunita A., Sato S., Kaneko M., Osawa M. Molecular identification of Aggrus/T1α as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem 2003, 278:51599-51605.
62. Kato Y., Kaneko M.K., Kuno A., Uchiyama N., Amano K., Chiba Y., et al. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem Biophys Res Commun 2006, 349:1301-1307.
63. Kaneko M.K., Kato Y., Kameyama A., Ito H., Kuno A., Hirabayashi J., et al. Functional glycosylation of human podoplanin: glycan structure of platelet aggregation-inducing factor. FEBS Lett 2007, 581:331-336.
64. Kunita A., Kashima T.G., Morishita Y., Fukayama M., Kato Y., Tsuruo T., et al. The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol 2007, 170:1337-1347.
65. Ogasawara S., Kaneko M.K., Price J.E., Kato Y. Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. Hybridoma (Larchmt) 2008, 27:259-267.
66. Saleh H.S., Merkel U., Geissler K.J., Sperka T., Sechi A., Breithaupt C., et al. Properties of an ezrin mutant defective in F-actin binding. J Mol Biol 2009, 385:1015-1031.
67. Lan M., Kojima T., Murata M., Osanai M., Takano K., Chiba H., et al. Phosphorylation of ezrin enhances microvillus length via a p38 MAP-kinase pathway in an immortalized mouse hepatic cell line. Exp Cell Res 2006, 312:111-120.
68. Gautreau A., Poullet P., Louvard D., Arpin M. Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 1999, 96:7300-7305.
69. Belkina N.V., Liu Y., Hao J.J., Karasuyama H., Shaw S. LOK is a major ERM kinase in resting lymphocytes and regulates cytoskeletal rearrangement through ERM phosphorylation. Proc Natl Acad Sci USA 2009, 106:4707-4712.
70. Endo K., Kondo S., Shackleford J., Horikawa T., Kitagawa N., Yoshizaki T., et al. Phosphorylated ezrin is associated with EBV latent membrane protein 1 in nasopharyngeal carcinoma and induces cell migration. Oncogene 2009, 28:1725-1735.
71. Perl A.K., Wilgenbus P., Dahl U., Semb H., Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998, 392:190-193.
72. Li G., Herlyn M. Dynamics of intercellular communication during melanoma development. Mol Med Today 2000, 6:163-169.
73. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985, 315:115-122.
74. Atsumi N., Ishii G., Kojima M., Sanada M., Fujii S., Ochiai A. Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431. Biochem Biophys Res Commun 2008, 373:36-41.